NL301169I2 - Ripretinib - Google Patents

Ripretinib

Info

Publication number
NL301169I2
NL301169I2 NL301169C NL301169C NL301169I2 NL 301169 I2 NL301169 I2 NL 301169I2 NL 301169 C NL301169 C NL 301169C NL 301169 C NL301169 C NL 301169C NL 301169 I2 NL301169 I2 NL 301169I2
Authority
NL
Netherlands
Prior art keywords
ripretinib
Prior art date
Application number
NL301169C
Other languages
English (en)
Original Assignee
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals Llc filed Critical Deciphera Pharmaceuticals Llc
Publication of NL301169I2 publication Critical patent/NL301169I2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
NL301169C 2012-06-07 2022-04-12 Ripretinib NL301169I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17208408.9A EP3366293B1 (en) 2012-06-07 2012-06-07 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
PCT/US2012/041378 WO2013184119A1 (en) 2012-06-07 2012-06-07 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EP12878321.4A EP2858646B1 (en) 2012-06-07 2012-06-07 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
NL301169I2 true NL301169I2 (nl) 2026-03-02

Family

ID=49712374

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301169C NL301169I2 (nl) 2012-06-07 2022-04-12 Ripretinib

Country Status (28)

Country Link
EP (3) EP2858646B1 (nl)
JP (1) JP5883195B2 (nl)
KR (1) KR101652229B1 (nl)
CN (3) CN110433162A (nl)
AU (1) AU2012327210B2 (nl)
BR (1) BR112014030577B1 (nl)
CA (1) CA2875970C (nl)
CY (1) CY1123377T1 (nl)
DK (2) DK3366293T3 (nl)
ES (2) ES2797252T3 (nl)
FR (1) FR22C1013I2 (nl)
HR (1) HRP20200864T1 (nl)
HU (2) HUE049958T2 (nl)
IL (1) IL236110A (nl)
LT (2) LT3366293T (nl)
LU (1) LUC00253I2 (nl)
MX (2) MX392372B (nl)
NL (1) NL301169I2 (nl)
NO (1) NO2022010I1 (nl)
PH (2) PH12018502294B1 (nl)
PL (1) PL3366293T3 (nl)
PT (2) PT3366293T (nl)
RS (1) RS60406B1 (nl)
RU (1) RU2664055C2 (nl)
SG (1) SG11201408133TA (nl)
SI (1) SI3366293T1 (nl)
SM (1) SMT202000302T1 (nl)
WO (1) WO2013184119A1 (nl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP6576325B2 (ja) 2013-03-15 2019-09-18 セルジーン シーエーアール エルエルシー ヘテロアリール化合物およびそれらの使用
RS62626B1 (sr) 2016-01-11 2021-12-31 Merck Patent Gmbh Derivati hinolin-2-ona
KR102794891B1 (ko) * 2017-05-30 2025-04-15 데시페라 파마슈티칼스, 엘엘씨 혈소판 유래 성장 인자 수용체 알파의 유전적 이상과 연관된 암 치료를 위한 1-[4-브로모-5-[1-에틸-7-(메틸아미노)-2-옥소-1,2-다이히드로-1,6-나프티리딘-3-일]-2-플루오로페닐]-3-페닐우레아 및 유사체의 용도
WO2019056990A1 (zh) * 2017-09-20 2019-03-28 浙江海正药业股份有限公司 1,2-二氢-1,6-萘啶类衍生物、其制备方法及其在医药上的用途
EP3746059B1 (en) * 2018-01-31 2026-03-04 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of gastrointestinal stromal tumors
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
WO2020185812A1 (en) * 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
AR118826A1 (es) 2019-05-03 2021-11-03 Kinnate Biopharma Inc Inhibidores de cinasas raf
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
FI4013412T3 (fi) 2019-08-12 2026-03-24 Deciphera Pharmaceuticals Llc Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon
US20240075041A1 (en) * 2019-10-04 2024-03-07 Blueprint Medicines Corporation Treatment of eosinophilic disorders with avapritinib
BR112022007612A2 (pt) 2019-10-24 2022-09-20 Kinnate Biopharma Inc Inibidores de raf quinases
PL4084779T3 (pl) 2019-12-30 2025-02-24 Deciphera Pharmaceuticals, Llc Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
KR102535840B1 (ko) * 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
US11407737B2 (en) 2020-09-18 2022-08-09 Kinnate Biopharma Inc. Inhibitors of RAF kinases
WO2022081469A1 (en) 2020-10-12 2022-04-21 Kinnate Biopharma Inc. Inhibitors of raf kinases
CN112625038A (zh) * 2020-12-31 2021-04-09 武汉九州钰民医药科技有限公司 制备瑞普替尼的方法
WO2022162690A1 (en) * 2021-01-28 2022-08-04 Dr. Reddy's Laboratories Limited Process for the preparation of ripretinib and solid state forms thereof
EP4326256A4 (en) 2021-04-23 2025-03-19 Pierre Fabre Medicament Treating cancer with a RAF inhibition
WO2023122322A1 (en) * 2021-12-24 2023-06-29 Teva Pharmaceuticals International Gmbh Improved processes for the preparation of ripretinib
CN114213411B (zh) * 2022-01-24 2023-06-30 成都伊诺达博医药科技有限公司 一种瑞普替尼的合成方法
CN118974036A (zh) 2022-02-03 2024-11-15 皮埃尔法布雷医药公司 Raf激酶的抑制剂
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4758349B2 (ja) * 2003-10-08 2011-08-24 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
DE102006030524A1 (de) * 2006-07-01 2008-01-03 Koch Transporttechnik Gmbh Verfahren und Vorrichtung zur Beseitigung von lockerem Material auf wellenförmigen Oberflächen gestampfter Kohle für die Verkokung
CN101553232A (zh) * 2006-09-14 2009-10-07 迪赛孚尔制药有限公司 用于治疗增殖性疾病的激酶抑制剂
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CN101528744A (zh) * 2006-10-20 2009-09-09 Irm责任有限公司 用于调节c-kit和pdgfr受体的组合物和方法
ATE551342T1 (de) * 2008-02-22 2012-04-15 Irm Llc Heterocyclische verbindungen und zusammensetzungen als c-kit- und pdgfr- kinasehemmer

Also Published As

Publication number Publication date
SI3366293T1 (sl) 2020-08-31
RU2014153920A (ru) 2016-07-27
CA2875970C (en) 2017-07-04
EP3366293B1 (en) 2020-03-11
SG11201408133TA (en) 2015-01-29
HUS2200017I1 (hu) 2022-06-28
EP3722296A3 (en) 2020-10-21
RU2664055C2 (ru) 2018-08-14
LTPA2022008I1 (nl) 2022-05-25
PT3366293T (pt) 2020-06-18
EP3722296A2 (en) 2020-10-14
HUE049958T2 (hu) 2020-11-30
SMT202000302T1 (it) 2020-07-08
CN104902895B (zh) 2019-03-29
WO2013184119A1 (en) 2013-12-12
MX392372B (es) 2025-03-24
BR112014030577B1 (pt) 2022-02-08
PH12014502757A1 (en) 2015-03-02
NO2022010I1 (no) 2022-04-07
LUC00253I2 (nl) 2025-03-04
EP2858646A1 (en) 2015-04-15
HK1209345A1 (en) 2016-04-01
PH12018502294A1 (en) 2020-11-04
CN110403938A (zh) 2019-11-05
RS60406B1 (sr) 2020-07-31
CA2875970A1 (en) 2013-12-12
PH12018502294B1 (en) 2024-02-28
EP3366293A1 (en) 2018-08-29
MX372814B (es) 2020-07-03
CN104902895A (zh) 2015-09-09
AU2012327210B2 (en) 2016-07-28
IL236110A0 (en) 2015-01-29
MX2020005712A (es) 2022-05-17
LT3366293T (lt) 2020-07-10
EP2858646A4 (en) 2015-09-02
DK3366293T3 (da) 2020-06-15
CY1123377T1 (el) 2021-12-31
ES2797252T3 (es) 2020-12-01
FR22C1013I2 (fr) 2022-12-30
KR101652229B1 (ko) 2016-08-30
BR112014030577A8 (pt) 2018-10-23
AU2012327210A1 (en) 2014-01-09
PT2858646T (pt) 2018-03-27
PL3366293T3 (pl) 2020-09-21
HRP20200864T1 (hr) 2020-08-21
IL236110A (en) 2016-11-30
DK2858646T3 (en) 2018-03-19
MX2014015024A (es) 2015-07-06
FR22C1013I1 (fr) 2022-06-17
ES2663605T3 (es) 2018-04-16
EP2858646B1 (en) 2017-12-20
JP2015520186A (ja) 2015-07-16
LTC3366293I2 (nl) 2024-11-25
KR20150053894A (ko) 2015-05-19
PH12014502757B1 (en) 2015-03-02
JP5883195B2 (ja) 2016-03-09
CN110433162A (zh) 2019-11-12

Similar Documents

Publication Publication Date Title
EP2763896A4 (en) UNMANUFACTURED AIRCRAFT WITH SEVERAL ROTORS
DK2859055T3 (da) Polymercoatings
EP2880683A4 (en) BVA INTERPOSER
DK2825087T3 (da) Otoscanner
DK2839013T3 (da) Ikke-disruptiv-gen-targetering
EP2809145A4 (en) CHLOROPLAST TRANSIT PEPTIDES
EP2814472A4 (en) DITHIOAMINE REDUCING AGENTS
EP2824794A4 (en) Charging cable
EP2847405A4 (en) DOOR CLOSURE SYSTEM
EP2805877A4 (en) UNDER HOOD
DK2873977T3 (da) Dobbeltdækker-rørdispenser
DE112012006109A5 (de) Okklusionsschienenanordnung
DK2854722T3 (da) Stomipose
EP2941099A4 (en) SWITCHING DEVICE
EP2831482A4 (en) Flange gasket
EP2816694A4 (en) FLAT CABLE WINDING DEVICE
EP2809729A4 (en) Siloxane polyether copolymers
EP2862179A4 (en) FUEL CURRENT INSPECTION PROBE
EP2869113A4 (en) DISPLAY DEVICE FOR VEHICLE
DE112012006214T8 (de) Wulstringwickler
DK2831122T3 (da) Anthocyanidin-kompleks
DE112012005566T8 (de) Seltenerdnanoverbundmagnet
DK2885638T3 (da) Molekylenet
EP2873363A4 (en) DIOPSIMETER
DK2858657T3 (da) Feijoafrugtekstrakt